DAU 6285

Drug Profile

DAU 6285

Latest Information Update: 16 Oct 2003

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG; Roche Palo Alto LLC
  • Class Antiarrhythmics; Antiemetics; Anxiolytics
  • Mechanism of Action Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Gastrointestinal disorders

Most Recent Events

  • 16 Oct 2003 Discontinued for Arrhythmias in Italy (unspecified route)
  • 16 Oct 2003 Discontinued for Arrhythmias in Germany (unspecified route)
  • 07 Jun 2003 Discontinued - Preclinical for Gastrointestinal disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top